Angelman syndrome drug GTX-102 misses Phase 3 endpoint, deal setback for Ultragenyx
Ultragenyx said its experimental Angelman syndrome therapy GTX-102 showed no benefit versus a sham in a large Phase 3 trial, ending earlier hopes from earlier results and creating a major hurdle for the company's profitability plans in the rare-disease space.